Team:
Thanks again to everybody who collaborated during our COVID-19 Study-A-Thon. As of this post, the respective global calls have been viewed more than 1800 times already on YouTube, a total that does not include the registrants that watched live or the people who watched the global final call live. The final call already had more than 300 views less than 17 hours after it was posted.
Slides for the respective presentations have been posted to the OHDSI COVID-19 home page, and please continue to check that page for further updates. The slides, along with time stamps for the different presentations, are also included in this post.
Please note as you go through this exciting research that all results are preliminary and will undergo further review as part of the publication process.
You can watch the closing call here.
PRESENTATIONS WITHIN THE #OHDSICOVID19 WRAP-UP CALL (Full Slidedeck)
Introduction – Daniel Prieto-Alhambra and Patrick Ryan (Slides)
Literature Review – Jennifer Lane (22:00 • Slides)
Data Network In Action – Kristin Kostka (26:10• Slides)
Phenotype Development – Anna Ostropolets (31:38• Slides)
Clinical Characterization of COVID-19 – Ed Burn (42:10 • Slides)
The Journey Through Patient-Level Prediction – Peter Rijnbeek (50:12 • Slides)
Prediction #1: Amongst Patients Presenting with COVID-19, Influenza, or Associated Symptoms, Who Are Most Likely to be Admitted to the Hospital in the Next 30 Days? – Jenna Reps (56:55 • Slides)
Prediction #2: Amongst Patients at GP Presenting with Virus or Associated Symptoms with/without Pneumonia Who Are Sent Home, Who Are Most Likely to Require Hospitalization in the Next 30 Days? – Ross Williams (1:08:42 • Slides)
Prediction #3: Amongst Patients Hospitalized with Pneumonia, Who Are Most Likely To Require Intensive Services or Die? – Aniek Markus (1:15:25 • Slides)
Estimation #1: Hydroxychloroquine – Daniel Prieto-Alhambra (1:23:32 • Slides)
Estimation #2: Safety of HIV/HepC Protease Inhibitors – Albert Prats (1:31:24 • Slides)
Estimation #3: Association of Angiotensin Converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers (ARB) on COVID Incidence and Complications – Daniel Morales (1:36:58 • Slides)
#OpenData4COVID19 – Seng Chan You (1:45:32 • Slides)
The Journey Ahead – Patrick Ryan (1:50:28 • Slides)
Questions & Answers – Daniel Prieto-Alhambra, Peter Rijnbeek and Patrick Ryan (2:08:15)